Facts of Pangraf Tacrolimus Capsules 0.5mg

Pangraf Tacrolimus Capsules 0.5mg is a medication used in the management of various autoimmune diseases, including but not limited to psoriasis, rheumatoid arthritis, and ulcerative colitis. Tacrolimus is a calcineurin inhibitor, which works by blocking the production of certain substances that trigger the immune system to attack healthy tissues. As a result, it helps to suppress the inflammation and prevent the damage caused by autoimmune diseases.

Pangraf is manufactured by Panacea Biotec Limited, an Indian pharmaceutical company. It is available in the form of capsules, with a dose of 0.5mg. The medication is prescribed by a healthcare professional and should be taken under their supervision.

Here are some important facts about Pangraf Tacrolimus Capsules 0.5mg:



  1. Uses

Pangraf Tacrolimus Capsules 0.5mg is used to manage autoimmune diseases, such as:

  • Psoriasis: a skin condition characterized by red, scaly patches on the skin
  • Rheumatoid arthritis: a chronic autoimmune disease that causes joint inflammation and pain
  • Ulcerative colitis: a type of inflammatory bowel disease that affects the large intestine

It is also used to prevent the rejection of organ transplantation.

  1. Dosage

The recommended dose of Pangraf Tacrolimus Capsules 0.5mg is different for each individual, and it depends on the medical condition and the response to treatment. It is usually taken once or twice a day, with or without food. The dose should be taken at the same time every day to ensure consistent absorption of the medication.

  1. Precautions

Pangraf Tacrolimus Capsules 0.5mg should not be used if you are allergic to tacrolimus or any of the inactive ingredients in the medication. It is also not recommended for use in individuals with liver or kidney disease, or for women who are pregnant or breastfeeding.

Additionally, the use of this medication may increase the risk of developing infections, cancer, and other serious side effects. Therefore, it is important to inform your healthcare professional about your medical history and any other medications you are taking.

  1. Side Effects

Common side effects of Pangraf Tacrolimus Capsules 0.5mg include:

  • Nausea
  • Diarrhea
  • Vomiting
  • Abdominal pain
  • Headache
  • Insomnia

In some cases, the use of this medication may also lead to more serious side effects, such as:

  • Weakness or fatigue
  • High blood sugar levels
  • Increased risk of infections
  • Elevated cholesterol levels
  • Decreased kidney function
  • Skin rashes

If you experience any of these side effects, it is important to seek medical attention immediately.

  1. Interactions

Pangraf Tacrolimus Capsules 0.5mg may interact with other medications, including antibiotics, antifungals, blood pressure medications, and immunosuppressants. It is important to inform your healthcare professional about all the medications you are taking, including over-the-counter drugs and herbal supplements.

  1. Storage

Pangraf Tacrolimus Capsules 0.5mg should be stored at room temperature, away from heat, moisture, and light. It should be kept out of reach of children and pets.

In conclusion, Pangraf Tacrolimus Capsules 0.5mg is a medication used to manage autoimmune diseases and prevent organ rejection. It is important to follow the instructions of your healthcare professional

Conclusion:

Pangraf (Tacrolimus) Capsules suppliers in India. Allevaire India Network New Delhi, INDIA.

Alleviare Life sciences Pvt. Ltd. is a consulting pharmaceutical company specialized in providing medicines under Named Patient Program/Manage Access Program. Named Patient Program/ Manage Access Program is a program designed by the government of India and governments of many countries worldwide for patients who have exhausted the treatment options available in their respective countries and are in need of latest medicines that are available in countries of Europe and USA.

The order for Pangraf (Tacrolimus) Capsules will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Location: FLOOR, S, 9, Green Park Ext Rd, Block J, Green Park Extension, Green Park, New Delhi, Delhi 110016, India

Comments

Post a Comment

Popular posts from this blog

Treatment for Acute Myeloid Leukemia: IDHIFA (Enasidenib)

Image
  In the world of oncology, breakthroughs in targeted therapies have opened new avenues for the treatment of various types of cancer. One such remarkable advancement is the introduction of IDHIFA (Enasidenib), a medication that has shown great promise in the fight against acute myeloidleukemia (AML) . Understanding IDHIFA and AML:  IDHIFA, known by its generic name Enasidenib, is an oral medication that targets a specific mutation known as isocitrate dehydrogenase 2 (IDH2). Mutations in the IDH2 gene are found in approximately 12-20% of AML patients. These mutations lead to the production of an abnormal form of the IDH2 enzyme, which plays a significant role in the development and progression of AML. Approved Indication: IDHIFA is specifically indicated for the treatment of adult patients with relapsed or refractory AML harboring an IDH2 mutation. It is not intended for use in patients with other types of leukemia or those without the IDH2 mutation. Accessing IDHIFA: Obtaining IDHIFA
Read more

What Patients Should Know about Early Access Programs- AlleviareIndia

Image
  Introduction: In the world of medical research and development, new treatments, drugs, and therapies are constantly being developed to address various health conditions. However, the journey from initial development to final approval by regulatory authorities can be a lengthy process, leaving many patients eagerly awaiting access to potentially life-saving treatments. This is where Early Access Programs (EAPs) come into play. In this article, we will explore what patients should consider when participating in an Early Access Program. Understand the Purpose and Eligibility Criteria: Before considering participation in an Early Access Program, it's important to understand its purpose. EAPs are designed to provide access to investigational treatments for patients who have exhausted all other available options and have a serious or life-threatening condition. Familiarize yourself with the eligibility criteria to determine if you meet the necessary requirements. Discuss with
Read more

Abatacept (Orencia)

Image
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy. Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion. It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied. Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communicatio
Read more